Richard D Kennedy
Overview
Explore the profile of Richard D Kennedy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stevenson L, Cairns L, Li X, Jammula S, Taylor H, Douglas R, et al.
Sci Rep
. 2024 Dec;
14(1):32121.
PMID: 39739112
The incidence of oesophageal adenocarcinoma (OAC) has risen six-fold in western countries over the last forty years but survival rates have only marginally improved. Hyperactivation of the PI3K-AKT-mTOR pathway is...
2.
Jurisic A, Sung P, Wappett M, Daubriac J, Lobb I, Kung W, et al.
Clin Transl Med
. 2024 Apr;
14(4):e1648.
PMID: 38602256
Background: Understanding how to modulate the microenvironment of tumors that are resistant to immune checkpoint inhibitors represents a major challenge in oncology.Here we investigate the ability of USP7 inhibitors to...
3.
Tovey H, Sipos O, Parker J, Hoadley K, Quist J, Kernaghan S, et al.
Clin Cancer Res
. 2023 Aug;
29(18):3691-3705.
PMID: 37574209
Purpose: The TNT trial (NCT00532727) showed no evidence of carboplatin superiority over docetaxel in metastatic triple-negative breast cancer (mTNBC), but carboplatin benefit was observed in the germline BRCA1/2 mutation subgroup....
4.
Pencik J, Philippe C, Schlederer M, Atas E, Pecoraro M, Grund-Groschke S, et al.
Mol Cancer
. 2023 Aug;
22(1):133.
PMID: 37573301
Prostate cancer (PCa) is a common and fatal type of cancer in men. Metastatic PCa (mPCa) is a major factor contributing to its lethality, although the mechanisms remain poorly understood....
5.
McCabe N, Stevenson L, Scanlon E, Douglas R, Kennedy S, Keminer O, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954391
Drug resistance limits the effectiveness of oesophageal adenocarcinoma (OAC) chemotherapies, leading to a poor prognosis for this disease. Elucidation of the underlying resistance mechanisms is key to enabling the identification...
6.
El Helali A, Plummer R, Jayson G, Coyle V, Drew Y, Mescallado N, et al.
Br J Cancer
. 2022 May;
127(1):92-101.
PMID: 35568736
Background: We aimed to assess the safety, tolerability and pharmacokinetics of a novel anti-angiogenic peptide. Methods: We used an open-label, multicentre, dose-escalation Phase I trial design in patients with solid...
7.
El Helali A, Wong C, Choi H, Chan W, Dickson N, Siu S, et al.
Sci Rep
. 2022 Mar;
12(1):3803.
PMID: 35264616
The efficacy of anti-angiogenic agents (AAAs) in epithelial ovarian cancer (EOC) remains unclear. Therefore, we conducted a systematic review and network meta-analysis (NMA) to synthesize evidence of their comparative effectiveness...
8.
Parkes E, Savage K, Lioe T, Boyd C, Halliday S, Walker S, et al.
Br J Cancer
. 2021 Nov;
126(2):247-258.
PMID: 34728791
Background: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this assay...
9.
Parkes E, Humphries M, Gilmore E, Sidi F, Bingham V, Phyu S, et al.
NPJ Breast Cancer
. 2021 Jun;
7(1):81.
PMID: 34172750
STING signaling in cancer is a crucial component of response to immunotherapy and other anti-cancer treatments. Currently, there is no robust method of measuring STING activation in cancer. Here, we...
10.
Foley K, Lavery A, Napier E, Campbell D, Eatock M, Kennedy R, et al.
Sci Rep
. 2021 Jun;
11(1):13061.
PMID: 34158588
18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake value (SUVmax) to a novel DNA-damage immune response...